Bristol Myers Squibb announced the presentation of extensive new data across its oncology portfolio and research pipeline at the upcoming European Society for Medical Oncology (ESMO) Congress 2025, taking place from October 17–21 in Berlin, Germany.
The company will highlight findings from more than 50 company-sponsored and investigator-led studies, spanning over 10 cancer types.
"This year's ESMO meeting is a testament to the continued advancement of our oncology portfolio and potential of our research pipeline, driven by novel mechanisms and unique modalities," said Anne Kerber, Senior Vice President, Head of Development, Hematology, Oncology and Cell Therapy. "These presentations demonstrate our significant progress in addressing diverse tumor types and hard-to-treat populations and reinforce our commitment to our goal of delivering the next generation of transformative medicines to patients."
Key Highlights from Bristol Myers Squibb at ESMO 2025:
First disclosure of results from a global Phase 1 study of izalontamab brengitecan (iza-bren; BL-B01D1), a potential first-in-class EGFRxHER3 bispecific antibody-drug conjugate (ADC) in metastatic non–small cell lung cancer (NSCLC) and other solid tumors. These findings, to be presented as a mini oral, supported the FDA’s Breakthrough Therapy Designation for iza-bren in previously treated EGFR-mutated NSCLC.
Late-breaking updates on progression-free survival (PFS) and first disclosure of overall survival (OS) from the CheckMate -8HW trial, evaluating Opdivo® (nivolumab) plus Yervoy® (ipilimumab) versus Opdivo or chemotherapy in MSI-H/dMMR metastatic colorectal cancer (mCRC) across first- and all-line settings (proffered paper, oral).
Five-year follow-up results from CheckMate -274, assessing Opdivo as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC) post-radical resection, covering disease-free survival (DFS), overall survival (OS), and circulating tumor DNA (ctDNA) outcomes (proffered paper, oral).
Nine-year final analysis of CheckMate -238, comparing adjuvant Opdivo versus Yervoy in patients with resected advanced melanoma, to be presented as a mini oral.